Determining the Prevalence of HIV-Related Neurological Disorders in the Asia Pacific
Study Details
Study Description
Brief Summary
This study will determine the prevalence of HIV-related neurological disorders in the countries of the Asia-Pacific Region.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This a cross-sectional study to determine the prevalence of HIV-related Neurological Disorders in the countries of the Asia-Pacific Region. Researchers will visit each country site for a period of 2-3 weeks and work with local investigators. Outpatients will be evaluated once-only for the presence of HIV-related symptomatic peripheral neuropathy and HIV-related Neurocognitive Impairment. Inpatients at the sites will be evaluated once-only for the presence of HIV dementia, cerebral toxoplasmosis, cerebral tuberculosis, cryptococcal meningitis, lymphoma, PML and CMV encephalitis.
The Primary outcomes are:
-
To determine the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites
-
To determine the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites
-
To determine the prevalence of central nervous system opportunistic infections and tumours at the APNAC-10 sites
The secondary outcomes are:
To determine the degree of cognitive impairment in patients presenting with HIV-related cognitive impairment at the APNAC-10 sites
-
To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior AIDS defining illnesses (ADIs) of patients presenting with HIV-related neurocognitive impairment and ADC at the APNAC-10 sites
-
To compare the prevalence of HIV-related neurocognitive impairment and ADC at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
-
To compare the prevalence of HIV-related neurocognitive impairment and ADC between the APNAC-10 sites
-
To describe the severity of symptoms of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites
-
To determine the CD4 cell counts, HIV viral loads HIV viral loads and prior ADIs of patients presenting with symptomatic peripheral sensory neuropathy at the APNAC-10 sites
-
To determine what proportion of symptomatic peripheral sensory neuropathy may be ascribed to HIV alone, to the use of nucleoside analogues
-
To compare the prevalence of symptomatic peripheral sensory neuropathy at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
-
To compare the prevalence of symptomatic peripheral sensory neuropathy between the APNAC-10 sites
-
To determine the prevalence of asymptomatic peripheral neuropathy
-
To describe the presenting symptoms and signs of patients presenting with CNS OIs and tumours at the APNAC-10 sites
-
To describe the neuroradiological findings of patients presenting with CNS OIs and tumours at the APNAC-10 sites
-
To determine the serological, culture and other diagnostic test results of patients presenting with CNS OIs and tumours at the APNAC-10 sites
-
To determine the CD4 cell counts, HIV viral loads and prior ADIs of patients presenting with CNS OIs and tumours at the APNAC-10 sites
-
To compare the prevalence of CNS OIs and tumours at the APNAC-10 sites to the published pre-HAART prevalence of these conditions in developed countries
-
To compare the prevalence of CNS OIs and tumours between the APNAC-10 sites
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients are HIV infected
-
Patients are eighteen years or older
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Alfred Hospital | Melbourne | Victoria | Australia | 3004 |
Sponsors and Collaborators
- National Institute of Mental Health (NIMH)
- The Alfred
- National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
- Principal Investigator: Edwina Wright, Dr, The Alfred
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 77/05